Stock BDTX BLACK DIAMOND THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Black Diamond Therapeutics, Inc.

Equities

BDTX

US09203E1055

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/04/2024 am IST 		5-day change 1st Jan Change
5.89 USD +15.26% Intraday chart for Black Diamond Therapeutics, Inc. +11.98% +109.61%
11/04 Black Diamond Therapeutics, Inc. Announces Board and Committee Changes CI
08/04 Wedbush Adjusts Price Target on Black Diamond Therapeutics to $16 From $10 After Market Confirmation for Drug, Maintains Outperform Rating MT

Evolution of the average Target Price on Black Diamond Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

09fee03f9753e2ac6.cLBx5K46fuE3O3dDXzfHuYvCDrsz0mCSgnDFD4yWIWI.JcEFkNpVEIdbbQIaMWCF3_iVQPRngQvW5hy2R8fvWDMEwAewzwsT2Hl-Og~dd7398e25f6713e6a65fb8df2979a310

Analyst Recommendations on Black Diamond Therapeutics, Inc.

Wedbush Adjusts Price Target on Black Diamond Therapeutics to $16 From $10 After Market Confirmation for Drug, Maintains Outperform Rating MT
Piper Sandler Initiates Black Diamond Therapeutics With Overweight Rating, $11 Price Target MT
Stifel Upgrades Black Diamond Therapeutics to Buy From Hold, Adjusts Price Target to $10 From $2 MT
HC Wainwright Upgrades Black Diamond Therapeutics to Buy From Neutral, Price Target is $11 MT
Wedbush Upgrades Black Diamond Therapeutics to Outperform From Neutral, Adjusts Price Target to $10 From $3 MT
Wedbush Lowers Price Target for Black Diamond Therapeutics to $3 From $4, Maintains Neutral Rating MT
Berenberg Bank Adjusts Black Diamond Therapeutics Price Target to $16 From $34, Maintains Buy Rating MT
Wedbush Downgrades Black Diamond Therapeutics to Neutral From Outperform, Citing BDTX-1535 Timeline, Likely BDTX-189 Discontinuation, 'Tough' Financing Environment; PT to $4 From $22 MT
HC Wainwright Downgrades Black Diamond Therapeutics to Neutral From Buy MT
Stifel Adjusts Price Target on Black Diamond Therapeutics to $4 From $10, Reiterates Hold Rating MT
BLACK DIAMOND THERAPEUTICS : Stifel Starts Black Diamond Therapeutics at Hold With $10 Price Target MT
BLACK DIAMOND THERAPEUTICS : Wedbush Lowers PT for Black Diamond Therapeutics to $22 From $48 Following BDTX-189 Data, Reiterates Outperform Rating MT
BLACK DIAMOND THERAPEUTICS : Berenberg Bank Adjusts Black Diamond Therapeutics PT to $34 From $58, Maintains Buy Rating MT
BLACK DIAMOND THERAPEUTICS : Wedbush Removes Outperform-Rated Black Diamond Therapeutics From Best Ideas List; Price Target is $48 MT
BLACK DIAMOND THERAPEUTICS : Wedbush Adds Outperform-Rated Black Diamond Therapeutics to Best Ideas List; Price Target is $48 MT
BLACK DIAMOND THERAPEUTICS : Wedbush Adjusts Price Target on Black Diamond Therapeutics to $48 From $45, Keeps Outperform Rating MT
BLACK DIAMOND THERAPEUTICS : Wedbush Starts Black Diamond Therapeutics at Outperform With $45 Price Target MT
BLACK DIAMOND THERAPEUTICS : Berenberg Starts Black Diamond Therapeutics at Buy With $58 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
5.89 USD
Average target price
12.8 USD
Spread / Average Target
+117.32%
High Price Target
16 USD
Spread / Highest target
+171.65%
Low Price Target
10 USD
Spread / Lowest Target
+69.78%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Black Diamond Therapeutics, Inc.

Wedbush
Piper Sandler
Stifel Nicolaus
HC Wainwright
Berenberg Bank

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. BDTX Stock
  4. Consensus Black Diamond Therapeutics, Inc.